2006
DOI: 10.1016/j.brachy.2006.02.003
|View full text |Cite
|
Sign up to set email alerts
|

PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: A study of 295 patients with a minimum 3-year followup

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
31
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 56 publications
(34 citation statements)
references
References 27 publications
3
31
0
Order By: Relevance
“…And in multivariate analysis, D90 greater than 180 Gy was identifi ed as an independent factor for a PSA bounce of at least 0.4 ng/ml. Stock et al 5 and Toledano et al 3 also showed a signifi cantly more frequent bounce rate for patients with a D90 greater than 160 Gy and a D90 greater than 200 Gy, respectively. Though it has been reported that no association was found between D90 and PSA bounce in the multi-institutional study of Japanese patients, 12 it is possible to explain the association of a PSA bounce with higher doses of radiation.…”
Section: Discussionmentioning
confidence: 91%
See 3 more Smart Citations
“…And in multivariate analysis, D90 greater than 180 Gy was identifi ed as an independent factor for a PSA bounce of at least 0.4 ng/ml. Stock et al 5 and Toledano et al 3 also showed a signifi cantly more frequent bounce rate for patients with a D90 greater than 160 Gy and a D90 greater than 200 Gy, respectively. Though it has been reported that no association was found between D90 and PSA bounce in the multi-institutional study of Japanese patients, 12 it is possible to explain the association of a PSA bounce with higher doses of radiation.…”
Section: Discussionmentioning
confidence: 91%
“…4,5,8,9,18,19 PSA bounce is a common phenomenon after brachytherapy. PSA bounce has previously been defi ned as an increase of more than 0.1 ng/ml, 3,5,8,9,12 followed by a subsequent decrease to less than that level; as an increase of more than 0.2 ng/ml, 2,3,6,7,11 followed by a decline or a minimal rise of 0.4 ng/ml 3,5,12 during a 3-6 month period, followed by a drop of any magnitude; or as a more than 35% elevation 5,12 in PSA compared with the most recent value, followed by a decline to a level at or less than the prebounce value. A rise of 0.1 ng/ml or 0.2 ng/ml may be too sensitive for clini- Table 2).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Several definitions have previously used: an increase of $0.1 ng/mL (11), $0.2 ng/mL (12,13), 0.4 ng/mL (14), or 0.5 ng/mL (15) or simply an increase of any magnitude (16). It has also been defined as an elevation in PSA between $15% and 35% above the nadir value (14,17,18).…”
Section: Discussionmentioning
confidence: 98%